Ftse Mib
34.657,35
0,93%
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
NASDAQ
16.340,87
-0,03%
Bitcoin
61.270,42
0,78%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Akebia Therapeutics Inc (AKBA) Akebia Therapeutics Inc (AKBA) Notizie

AKBA

Akebia Therapeutics (AKBA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKBA
DataOraFonteTitoloSimboloCompagnia
09/05/202423:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
09/05/202413:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKBAAkebia Therapeutics Inc
09/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKBAAkebia Therapeutics Inc
09/05/202413:00PR Newswire (US)Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
02/05/202414:30PR Newswire (US)Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
01/05/202422:05PR Newswire (US)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AKBAAkebia Therapeutics Inc
28/03/202401:26PR Newswire (US)Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisNASDAQ:AKBAAkebia Therapeutics Inc
14/03/202421:15PR Newswire (US)Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
11/03/202422:05PR Newswire (US)Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:AKBAAkebia Therapeutics Inc
29/02/202422:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
30/01/202422:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKBAAkebia Therapeutics Inc
30/01/202414:00PR Newswire (US)Akebia Secures $55 Million Term Loan FinancingNASDAQ:AKBAAkebia Therapeutics Inc
18/01/202423:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
09/01/202414:30PR Newswire (US)Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial OfficerNASDAQ:AKBAAkebia Therapeutics Inc
20/12/202314:00PR Newswire (US)Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
20/11/202314:00PR Newswire (US)Akebia Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
08/11/202313:30PR Newswire (US)Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
02/11/202321:30PR Newswire (US)Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon AdvisorsNASDAQ:AKBAAkebia Therapeutics Inc
31/10/202313:00PR Newswire (US)Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
25/10/202314:30PR Newswire (US)Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseaseNASDAQ:AKBAAkebia Therapeutics Inc
18/10/202314:00PR Newswire (US)Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023NASDAQ:AKBAAkebia Therapeutics Inc
28/09/202314:00PR Newswire (US)Akebia Therapeutics Resubmits New Drug Application to the FDA for VadadustatNASDAQ:AKBAAkebia Therapeutics Inc
26/09/202314:00PR Newswire (US)Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial UpdateNASDAQ:AKBAAkebia Therapeutics Inc
06/09/202314:00PR Newswire (US)Akebia Therapeutics to Present at H.C. Wainwright Global Investment ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
28/08/202314:55Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:AKBAAkebia Therapeutics Inc
25/08/202314:09PR Newswire (US)Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
24/08/202314:00PR Newswire (US)Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023NASDAQ:AKBAAkebia Therapeutics Inc
23/08/202322:35PR Newswire (US)Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
17/08/202322:05PR Newswire (US)Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023NASDAQ:AKBAAkebia Therapeutics Inc
10/08/202323:40PR Newswire (US)Akebia Therapeutics Provides Update on Form 10-Q FilingNASDAQ:AKBAAkebia Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKBA

La tua Cronologia

DOWI
DJSOEP
DJ US Select Oil Explora...
BIT
I07854
Intesa Sanpaolo
EU
TPAB5
Euronext Transatlantic P...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network